• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

J&J’s big block­buster hope­ful es­ke­t­a­mine scores high for ma­jor de­pres­sion — but side ef­fects haunt re­sults

8 years ago
R&D

On a deal spree, Mallinck­rodt bags Su­cam­po and two late-stage rare dis­ease drugs for $1.2B

8 years ago
Deals

No­var­tis' Tafin­lar/Mekin­ist com­bo for melanoma gets pri­or­i­ty re­view des­ig­na­tion; Fo­s­un Phar­ma backs joint ven­ture's ...

8 years ago
News Briefing

Syn­er­gy CEO pass­es torch to CCO Troy Hamil­ton; Pres­i­dent Steven Kaf­ka re­signs from Foun­da­tion; Ab­b­Vie vet John ...

8 years ago
Peer Review

De­nied: FDA re­jects Ag­ile's con­tra­cep­tion patch for sec­ond time

8 years ago
R&D

Cel­gene shares sink af­ter an­oth­er PhI­II lym­phoma flop and J&J steps up for the late-stage BC­MA race

8 years ago
R&D
Pharma

The FDA just ap­proved the 46th new drug of the year — a record high for the past decade

8 years ago
Pharma

Roche lines up at the FDA's 10-yard line with $1.7B Igny­ta buy­out

8 years ago
Deals

J&J wows with a $350M cash deal to part­ner on CAR-T with Leg­end, a one-time un­known un­til its star turn at AS­CO

8 years ago
R&D
Pharma

Fol­low­ing can­cer com­bo deal with Bris­tol-My­ers, Taris gets $25M Se­ries B

8 years ago
Financing

Tra­con inks deal with Am­brx to de­vel­op can­cer drug in Chi­na; Roche wins con­sec­u­tive ap­provals in EU and US

8 years ago
News Briefing

Kym­ri­ah, Yescar­ta found 'cost-ef­fec­tive' in treat­ing can­cer, de­spite high price

8 years ago
Pharma

Look­ing for an ear­ly suc­cess in PhII Alzheimer’s study, Bio­gen and Ei­sai just racked up the lat­est set­back

8 years ago
R&D

Google backs a $60M tran­si­tion round for FLX’s switch to a CCR4 strat­e­gy

8 years ago
Startups

Mer­ck, Pfiz­er make a late — very late — ar­rival at the SGLT2 par­ty for di­a­betes

8 years ago
Pharma

Backed by Hen­ri Ter­meer es­tate, Au­ra rais­es $30M for work to pre­vent blind­ness in eye can­cer pa­tients

8 years ago
Financing

In gene ther­a­py's sec­ond big win this week, Or­chard nabs $110M Se­ries B

8 years ago
Financing
Startups

Bris­tol-My­ers takes a stake in Taris Bio­med­ical; Zai Lab, Five Prime strike a deal to de­vel­op tu­mor im­munother­a­py in ...

8 years ago
News Briefing

An­oth­er death mars Ab­b­Vie's lat­est batch of promis­ing da­ta for its star rheuma­toid arthri­tis drug

8 years ago
R&D

Flag­ship adds $618M in new funds to fu­el start­up mis­sion

8 years ago
Financing
Startups

A US sen­a­tor calls out a lit­tle biotech for price goug­ing. But will it change any­thing?

8 years ago
Pharma

Af­ter ax­ing a top drug, Mil­len­do bags a PhII re­place­ment with biotech buy­out

8 years ago
Deals

GAO re­port tracks the growth of an $89B drug R&D sec­tor as bio­phar­ma sales soared

8 years ago
R&D

With AveX­is com­ing up in the rear view mir­ror, Bio­gen and Io­n­is go back to the draw­ing board on SMA

8 years ago
R&D
Pharma
First page Previous page 1060106110621063106410651066 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.